Although some clinical drugs were found to be positive for liver fibrosis treatment in clinical trails including PPAR-γ agonist (pioglitazone), angiotensin receptor blockers (losartan, telmisartan, olmesartan and candesartan), and glucagon-like peptide-1 receptor agonists (liraglutide), the safety and effect of these drugs need to be further confirmed (Georgescu, 2008; Mantovani et al., 2021). Here, PPARG is linked to Hepatic fibrosis.